Compare ADMA Biologics Inc (ADMA) vs Devon Energy Corp (DVN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Devon Energy Corp — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Devon Energy Corp trades at $42.95 (market cap $48.92B). The key difference: Devon Energy Corp is far larger — about 23× ADMA Biologics Inc's market cap, and Devon Energy Corp pays a 2.45% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | DVN | |
|---|---|---|
Market Cap | $2.13B | $48.92B |
Sector | Health | Energy |
52-Week High | $20.38 | $52.07 |
52-Week Low | $7.60 | $31.74 |
Enterprise Value | $2.20B | $55.69B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Devon Energy (DVN) trades at $42.41, up 4.79% on the day, with a bearish technical signal but bullish oscillators. The stock shows strong profitability with a 13.71% net margin and trades at a P/E of 11.24, below sector averages. Recent news highlights activist pressure for asset sales and a pending Q2 2026 earnings report on August 4, 2026.
DVN presents a value opportunity with a consensus price target of $61.60, implying 45% upside, supported by a 71% buy rating from analysts. Risks include oil price volatility, execution of the Coterra merger synergies, and activist investor demands. The company's disciplined capital allocation and strong cash flow generation underpin the bullish outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Devon Energy Corp
Devon Energy, based in Oklahoma City, is one of the largest independent exploration and production companies in North America. The firm's asset base is spread throughout onshore North America and includes exposure to the Delaware, STACK, Eagle Ford, Powder River Basin, and Bakken plays. At year-end 2021, Devon's proved reserves totaled 1.6 billion barrels of oil equivalent, and net production that year was 572 thousand boe/d, of which oil and natural gas liquids made up 74% of production, with natural gas accounting for the remainder.
Read more on DVN →
